每经AI快讯，有投资者在投资者互动平台提问：二季度业务回暖了吗？ 欧普康视（300595.SZ）8月11日在投资者互动平台表示，二季度经营情况请关注8月23日披露的2025年 半年报。 （文章来源：每日经济新闻） ...

证券代码：300595 证券简称：欧普康视 公告编号：2025-062 欧普康视科技股份有限公司 《还款银行回单》 特此公告。 欧普康视科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、财务资助事项概述 欧普康视科技股份有限公司（以下简称"公司"）于 2024 年 8 月 15 日召 开第四届董事会第十一次会议和第四届监事会第十一次会议，审议通过了《关 于控股子公司向参股子公司提供财务资助的议案》。为满足公司控股子公司陕 西奥泰克医疗科技有限公司（以下简称"陕西奥泰克"）参股公司西安粉象视 光科技有限公司（以下简称"西安粉象"）日常生产经营所需的资金需求，保 障其业务正常开展，陕西奥泰克向参股公司西安粉象按其持股比例提供 157.5 万元的财务资助，借款期限 2024 年 8 月 15 日起，2025 年 8 月 31 日止（以实际 款项到账日起一年期），按年利率 3%收取利息，按季付息，一次还本。具体内 容详见公司于 2024 年 8 月 16 日在巨潮资讯网（http://www.cninfo.com.cn） 披露的《关于控股子公司对外 ...

欧普康视（300595.SZ）8月7日在投资者互动平台表示，跨境电商主要销售一些日常的眼健康用品，目 前马来西亚已启动，其它东南亚国家在筹备中。公司的主营产品角膜塑形镜、巩膜镜、护理品等属于医 疗器械，需要先在当地注册才能销售，注册在准备中。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：董秘，您好！早段时间公司有信息说电商进行海外布 局，并在部分国家申请证照，具体正在进行或计划的有那些国家、地区？ ...

（文章来源：证券日报） 证券日报网讯 7月31日晚间，欧普康视发布公告称，公司于2025年7月3日召开第四届董事会第十六次会 议和第四届监事会第十六次会议、于2025年7月22日召开2025年第一次临时股东大会，分别审议通过了 《关于变更部分募集资金用途并用于收购宿迁市尚悦启程医院管理有限公司75%股权的议案》，同意公 司使用33，390.00万元收购宿迁市尚悦启程医院管理有限公司75%股权，其中使用募集资金23，373.00 万元，自有资金10，017.00万元，同时提请股东大会授权公司董事长或其指定的授权对象办理与上述项 目变更和实施有关的所有事项，以及开立募集资金专户、签署募集资金多方监管协议等相关事宜。近 日，公司在兴业银行股份有限公司合肥分行开立募集资金专项账户，且公司、国元证券股份有限公司及 兴业银行股份有限公司合肥分行签署了《募集资金三方监管协议》。 ...

欧普康视科技股份有限公司（以下简称"公司"）于 2025 年 7 月 3 日召开 第四届董事会第十六次会议和第四届监事会第十六次会议、于 2025 年 7 月 22 日 召开 2025 年第一次临时股东大会，分别审议通过了《关于变更部分募集资金用 途并用于收购宿迁市尚悦启程医院管理有限公司75%股权的议案》，同意公司使 用 33,390.00 万元收购宿迁市尚悦启程医院管理有限公司 75%股权，其中使用募 集资金 23,373.00 万元，自有资金 10,017.00 万元，同时提请股东大会授权公 司董事长或其指定的授权对象办理与上述项目变更和实施有关的所有事项，以 及开立募集资金专户、签署募集资金多方监管协议等相关事宜。具体内容详见 公司于 2025 年 7 月 5 日在巨潮资讯网（http://www.cninfo.com.cn）披露的 《关于变更部分募集资金用途并用于收购宿迁市尚悦启程医院管理有限公司75% 股权的公告》。 近日，公司、国元证券股份有限公司及兴业银行股份有限公司合肥分行签 署了《募集资金三方监管协议》，具体情况如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意欧普康视科技 ...

Group 1 - The stock price of Oupankangshi on July 30 was 18.12 yuan, a decrease of 0.08 yuan, representing a decline of 0.44% from the previous trading day [1] - The trading volume on that day was 258,927 hands, with a total transaction amount of 472 million yuan [1] - As of July 18, 2025, the total number of shareholders for Oupankangshi was 62,918 [1] Group 2 - The company's main business involves the research, development, production, and sales of ophthalmic medical devices [1] - Key products include orthokeratology lenses and rigid gas permeable contact lenses [1] - On July 30, the net inflow of main funds was 5.5334 million yuan [1]

证券日报网讯欧普康视（300595）7月30日在互动平台回答投资者提问时表示，截至2025年7月18日，公 司股东总人数为62918户。 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [1][40]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [4][14]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [4][15]. - Approximately 91% of stocks in the industry achieved positive returns, with notable performers including Borui Pharmaceutical, which saw a weekly increase of 78.98% [16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025, surpassing the CSI 300 by about 4.13 percentage points [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [15]. - About 91% of stocks in the industry had positive returns, with Borui Pharmaceutical leading at 78.98% [16]. 2. Industry News - The report highlights the ongoing progress of the 11th batch of national drug procurement, with significant updates provided during a government open day event on July 22, 2025 [4][28]. - The announcement of the 11th batch of national drug procurement included a notification for drug information submission, which was highly anticipated [4][28]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of YKYY029 injection for hypertension treatment [29]. 4. Industry Outlook - The report maintains an "Overweight" rating for the industry, citing a continuous rise in the pharmaceutical and biotechnology sector driven by positive sentiment towards innovative drugs and improved financing data [30]. - The report suggests focusing on investment opportunities within the innovative drug supply chain and highlights several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [30][32].

Core Viewpoint - The medical device industry experienced a slight decline of 0.02% on July 23, with a total capital inflow of 23.87 million [1] Group 1: Market Performance - A total of 49 stocks in the sector rose, while 71 stocks fell [1] - The top ten decliners included: - JinHao Medical (-6.2%) - WeiSi Medical (-6.18%) - BeiYiKang (-5.91%) - Rejing Biology (-5.1%) - AiPeng Medical (-3.78%) - DiRui Medical (-3.55%) - YingKe Medical (-2.78%) - AiWei Technology (-2.58%) - YiRui Technology (-2.46%) - KangTuo Medical (-2.35%) [1] Group 2: Capital Flow - The net capital outflow for the top decliners included: - JinHao Medical: -15.52 million - WeiSi Medical: -13.50 million - BeiYiKang: -9.36 million - Rejing Biology: -14.75 million - AiPeng Medical: -15.57 million [1] Group 3: Top Gainers - The top gainers in the sector included: - OuPuKangShi (14.13%) - TouJing Life (5.7%) - KangZhong Medical (5.07%) - TianYi Medical (4.97%) - AoTai Biology (3.52%) [1]

Market Overview - As of 10:29 AM today, the Shanghai Composite Index stands at 3592.77 points, above the annual line, with a change of 0.30% [1] - The total trading volume of A-shares today is 857.68 billion yuan [1] Stocks Breaking Annual Line - A total of 27 A-shares have surpassed the annual line today, with notable stocks including: - Opcon Vision (300595) with a deviation rate of 9.58% - Mars (300894) with a deviation rate of 6.80% - Xianju Pharmaceutical (002332) with a deviation rate of 3.03% [1] Deviation Rate Rankings - The following stocks have the highest deviation rates from the annual line: - Opcon Vision: Today's increase of 12.38%, turnover rate of 3.83%, annual line at 16.41 yuan, latest price at 17.98 yuan [1] - Mars: Today's increase of 8.18%, turnover rate of 8.48%, annual line at 13.62 yuan, latest price at 14.55 yuan [1] - Xianju Pharmaceutical: Today's increase of 5.12%, turnover rate of 5.68%, annual line at 10.36 yuan, latest price at 10.67 yuan [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the annual line include: - Beiqi Blue Valley (600733) with a deviation rate of 0.03% - Qianhe Flavor (603027) with a deviation rate of 0.05% - Luyang Energy (002088) with a deviation rate of 0.15% [2]